News & Media

News

May 23, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC)

COLUMBUS, OH, May 23, 2024 – Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and...

News

March 25, 2024

Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency

COLUMBUS, OH, March 25, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

News

February 28, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)

COLUMBUS, OH, February 28, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

News

January 15, 2024

Andelyn Biosciences and Armatus Bio Partner to Manufacture Suspension-Based AAV Gene Therapy for Rare Neurological Disease Charcot-Marie-Tooth Type 1A (CMT1A)

COLUMBUS, OH, January 15, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

News

November 20, 2023

Battelle, Andelyn Biosciences, and AmplifyBio Awarded Task Orders for Plasmid and Suspension AAV Vector Manufacturing and IND-enabling Studies from the National Institute of Neurological Disorders and Stroke (NINDS)

COLUMBUS, OH, Nov 20, 2023 – Battelle, Andelyn Biosciences, Inc., and AmplifyBio, have been awarded a new task order from the...

Connect Here With Our Business Team